DETECTION & QUANTITAION OF DRUG RESISTANT MUTANTS OF HIV

描述（改编自申请人的摘要）：众所周知， 随着时间的推移，艾滋病毒的抗药性突变形式在个体中出现。因此，我们认为， 即使在开始治疗之前， 因此可以确定对于给定个体的最佳药物组合。在 在没有药物的情况下，耐药突变体的数量往往比 野生型病毒随着治疗的进展，这些存活的病毒库中的大部分都是 整合到宿主DNA中的基因因此，监测潜伏病毒 基因组在治疗监测中是必需的。因此，非常敏感和定量 用于监测DNA中每种耐药性的存在的方法 HIV-1菌株非常重要。BioTraces开发了强大的DNA 基于定量PCR分析和多光子检测的诊断 技术. BioTraces还开发了MPD增强的多个定量 PCR的灵敏度是几个拷贝，它可以测量相当偏斜， 两种不同的DNA靶标之间的比率。开发MPD增强 提出了监测耐药HIV-1病毒株的技术。 拟定商业应用：不可用

DESCRIPTION (Adapted from the Applicant's Abstract): It is well known that drug-resistant mutant forms of HIV arise in individuals over time. Therefore, it is important to check for drug-resistance even before initiating treatments so the best drug combination for a given individual can be determined. In the absence of drug, drug-resistant mutants are often much less abundant than wild-type virus. As treatment progresses, much of this surviving virus pool is that which is integrated into the host DNA. Thus, monitoring for latent viral genomes is needed in therapy monitoring. Thus, very sensitive and quantitative methods for monitoring DNA for the presence of each and every drug resistant strain of HIV-1 are very important. BioTraces has developed powerful DNA diagnostics based on quantitative PCR assay and MultiPhoton Detection technology. BioTraces has also developed MPD enhanced multiple quantitative PCR, the sensitivity of which is a few copies, and it can measure quite skewed ratios between the two different DNA targets. Development of MPD enhanced techniques for monitoring drug resistant HIV-1 strains is proposed. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE